Clinical Trials
14 trialsNCT00064350 2023-06-29
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT01248247 2022-01-12
BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00754923 2019-03-06
Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Terminated
NCT00547443 2019-01-10
Sorafenib and High-Dose Carboplatin, Paclitaxel, and External-Beam Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
University of Texas Southwestern Medical Center
Phase 1/2 Withdrawn
NCT00543335 2018-11-15
Sorafenib and Thoracic Radiation for Patients With Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT00703638 2017-11-29
Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors
Masonic Cancer Center, University of Minnesota
Phase 1 Completed
NCT00454194 2017-03-21
Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00411671 2016-02-11
BATTLE Program: Sorafenib in Patients With NSCLC
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00533585 2016-02-10
BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC)
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00466232 2015-12-16
Phase I Study of Weekly Topotecan in Combination With Sorafenib in Treatment of Relapsed Small Cell Lung Cancer
HealthPartners Institute
Phase 1 Completed
NCT00726986 2014-11-19
Sorafenib, Cisplatin, and Etoposide in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Case Comprehensive Cancer Center
Phase 2 Terminated
NCT01069328 2013-11-13
Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC)
Bayer
Phase 1 Completed
NCT00456716 2010-03-04
Sorafenib in BAC or Never-Smokers With Lung Adenocarcinoma
Swedish Medical Center
Phase 2 Completed
NCT00801385 2009-08-25
Sorafenib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Chemotherapy
National Cancer Institute (NCI)
Phase 2 Unknown